Drug Type Small molecule drug |
Synonyms Prilinostat Mesylate |
Target |
Mechanism HDAC inhibitors(Histone deacetylase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePhase 2/3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diffuse Large B-Cell Lymphoma | Phase 3 | CN | 22 Mar 2024 | |
Plasma cell myeloma refractory | Phase 2 | CN | 26 Jun 2024 | |
Advanced Malignant Solid Neoplasm | Phase 2 | CN | 23 Apr 2024 | |
Advanced Malignant Solid Neoplasm | Phase 2 | CN | 23 Apr 2024 | |
Cutaneous T-Cell Lymphoma | Phase 2 | CN | 22 Nov 2023 | |
Peripheral T-Cell Lymphoma | Phase 2 | CN | 22 Nov 2023 | |
Diffuse large B-cell lymphoma recurrent | Phase 2 | CN | 08 Nov 2022 | |
Acute Lymphoblastic Leukemia | Phase 2 | CN | 30 Jan 2022 | |
Multiple Myeloma | Phase 2 | CN | 30 Jan 2022 | |
T-Cell Leukemia | Phase 2 | CN | 30 Jan 2022 |
NCT05563844 (ASCO2024) Manual | Phase 2 | Diffuse Large B-Cell Lymphoma double-expressor (DEL) | TP53 abnormal | 28 | xuaziajbpb(twvkuupevs) = mayizihyao hidrizfywq (wtdlvqjaie, 38.4 - 88.2) View more | Positive | 02 Jun 2024 | |
xuaziajbpb(twvkuupevs) = bjqdoyigat hidrizfywq (wtdlvqjaie, 46.2 - 95.0) | |||||||
Phase 1 | 18 | ktabztrzay(smlpmkfdhr) = aehznaxwha srwejiytso (koqgunpdiq ) View more | Positive | 09 Jun 2023 |